Intellipharmaceutics International Inc.
IPCIQ
$0.00
$0.000.00%
OTC PK
| 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | 08/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 958.36% | 1,188.10% | 134.73% | 23.34% | -78.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 782.83% | 925.54% | 112.16% | 41.54% | -73.91% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -69.56% | 925.54% | 112.16% | 41.54% | -73.91% |
| SG&A Expenses | 34.51% | -75.16% | -68.03% | -56.31% | -61.17% |
| Depreciation & Amortization | -21.15% | -21.17% | -21.15% | -21.22% | -27.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.23% | -56.45% | -37.01% | -30.65% | -15.23% |
| Operating Income | 32.52% | 74.48% | 43.30% | 32.26% | 9.79% |
| Income Before Tax | 22.50% | 68.85% | 54.72% | 45.11% | 14.45% |
| Income Tax Expenses | 104.64% | 104.64% | 104.64% | 104.64% | -448.17% |
| Earnings from Continuing Operations | 20.13% | 68.02% | 53.60% | 43.78% | 17.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.13% | 68.02% | 53.60% | 43.78% | 17.41% |
| EBIT | 32.52% | 74.48% | 43.30% | 32.26% | 9.79% |
| EBITDA | 33.64% | 77.71% | 45.06% | 33.37% | 8.43% |
| EPS Basic | 26.92% | 73.54% | 60.41% | 54.03% | 33.96% |
| Normalized Basic EPS | 37.11% | 80.50% | 53.81% | 47.57% | 56.45% |
| EPS Diluted | 30.22% | 74.09% | 58.32% | 49.80% | 28.62% |
| Normalized Diluted EPS | 37.11% | 80.50% | 53.81% | 47.57% | 56.45% |
| Average Basic Shares Outstanding | 11.07% | 11.07% | 15.72% | 24.98% | 22.30% |
| Average Diluted Shares Outstanding | 11.07% | 11.07% | 15.72% | 24.98% | 22.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |